Coromandel International to Review Q2 FY27 Results Today
Key highlights
- Coromandel International's board will consider Q2 FY27 and half-year results on November 6, 2026.
- June 2026 consolidated sales were ₹8,165 crore, up 16% year on year.
- June 2026 EBITDA was ₹756 crore, down 3% year on year.
- June 2026 consolidated net profit was ₹382 crore, down 24% year on year.
powered by IRIS

Coromandel International Limited will consider and approve its unaudited standalone and consolidated results for Q2 FY27 and the half year ended September 30, 2026, at its board meeting on November 6, 2026, following June-quarter consolidated sales of ₹8,165 crore and net profit of ₹382 crore.
Know Coromandel International inside out
Results, valuation, peers and who's buying, in one view.
When will Coromandel International announce Q2 FY27 results?
Coromandel International will consider its July-September 2026 financial results at a board meeting scheduled for Friday, November 6, 2026. The company informed the exchanges on November 3 that directors would consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
The scheduled meeting falls 37 days after the September quarter ended, according to the results calendar information provided. The company’s previous results board meeting was held on July 23, 2026, for Q1 FY27. The current meeting is specifically focused on quarterly results, and the reported numbers were not yet available on the NSE-linked results page at the time of the announcement.
Coromandel International had also announced that its trading window would close from October 1, 2026, and remain closed until 48 hours after the September-quarter unaudited results are declared. The closure was stated to be in line with SEBI insider-trading norms.
What do Coromandel International's latest disclosed quarterly figures show?
The latest consolidated figures supplied for the June 2026 quarter show sales of ₹8,165 crore, up 16% year on year from ₹7,042 crore in June 2025. EBITDA was ₹756 crore, down 3% from ₹782 crore, while net profit declined 24% to ₹382 crore from ₹502 crore.
The June-quarter comparison also shows sequential growth from March 2026, when sales were ₹6,004 crore, EBITDA was ₹488 crore and net profit was ₹115 crore. The data therefore indicates a higher revenue base in June than in the preceding quarter, although EBITDA and net profit remained below the respective June 2025 levels.
A separate quarterly financial table reports total income of ₹8,214.58 crore, EBIT of ₹602.70 crore and profit after tax of ₹380.82 crore for June 2026. These figures are presented separately from the consolidated sales, EBITDA and net-profit table. The company’s November 6 filing is expected to provide the next set of official standalone and consolidated financial statements for the September period.
Got a follow-up? Ask IRIS
How does the September review fit into Coromandel International's reporting cycle?
The September-quarter review covers both Q2 FY27 and the first half of FY27. This makes the board meeting important because the company will consider results for the three months ended September 30 as well as cumulative financial performance for the six months from April through September.
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, under Regulation 31(1)(b). It also submitted a dematerialisation and rematerialisation certificate to NSE and BSE on October 9 for the same quarter, with KFin Technologies Limited named as registrar and share transfer agent.
The available disclosures also refer to a board-meeting intimation dated November 3 and an earlier market notice that described the November 6 agenda as quarterly results. These notices establish the meeting date and scope, but they do not disclose the September-quarter revenue, margins, profit or any operational metric before the board considers the accounts.
What should investors assess when the Q2 FY27 results are released?
Investors will be able to compare the September-quarter figures with the June-quarter base, when consolidated sales rose 16% year on year but EBITDA and net profit fell 3% and 24%, respectively. That comparison will show whether revenue growth translated into operating profit and earnings during the next quarter.
The half-year statements will also provide a clearer view of the company’s performance across the first six months of FY27. Until the board-approved filing is released, there is no confirmed September-quarter financial outcome in the supplied disclosures, so conclusions on sales growth, margins or profit trends would be premature.
Coromandel International is identified in the supplied material as an F&O stock, which can increase market attention around scheduled financial disclosures. The immediate market relevance of the meeting is therefore the availability of new audited-by-review financial information, rather than any result estimate ahead of the announcement.
Conclusion
Coromandel International’s board meeting on November 6 is scheduled to approve unaudited Q2 FY27 and first-half FY27 results. The June-quarter figures provide the most recent financial reference in the supplied data: sales were ₹8,165 crore, while EBITDA and net profit were ₹756 crore and ₹382 crore, respectively.
The key item to watch next is the exchange filing following the board meeting, which will disclose the company’s standalone and consolidated September-quarter and half-year numbers. Investors can then assess the movement in sales, operating profit and net profit against both June 2026 and September 2025.


